New inhaled treatment aims to save lungs and reduce ventilator time in ICU patients

This study tests whether an inhaled drug called aprotinin can improve outcomes for adults with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. About 156 critically ill patients in intensive care will receive either aprotinin or a placebo, alongside standard care. The main goal is to see if the drug helps patients spend more days off a ventilator and reduces the risk of death within 28 days.